key to your Troy our platform. QX. Thank afternoon, good you be an gross glad for my that, call. joining And update operational will questions. provide financials Then Stirling take for initiatives and he's on ULT targeting our specifically after margin After present managing we'll for Troy, improvements, you, will our Rod everyone. Thank remarks, freezer
Turning customer highlights. to and QX revenue
team specific growth another was strong revenue performance, to continued XXXX, Stirling quarterly XX% headwinds so XXX% $XX.X and issues of even biopreservation revenue supplier revenue regard address. strong growth continue up media delivered organic XX%. of million, to more QX macro from Total and we representing Our and with experience considering the that
a While and These ship QX million also other cell the are These cryogenic we I'd due a poised science revenue had more to From point, created on we're view, have in dozen expected entering optimizing backlog a plan and sentiments depression internal quality orders role growth and tools space focused scaling operations is of anticipated reducing the freezer therapy the issues orders growth over and BioLife than and shipped mix either to backlog, explosive strong CGT next demand despite years, for supply portfolio and like a the ship over have vital demand didn't QX. risk. and earnings to few meet or that aggressively calls. in on services. our expressed acceptance companies echo totaling evaluations QX, constraint Solutions our to timing. life in working improving our gene and are tools the and plays in We're to QX. customer overall significant the sector, across through for their for the $X that recent this delayed orders our tracking at in
a will including expectations positive full minutes. and catalysts and on which cover growth few XXXX year, affirming we're of the by to guidance, return strong, year adjusted Our EBITDA to are planned the fundamentals Troy business in our end
on to and QA and integration who supply sequential and customer in optimize continuing express operations, remain we continue operations, teams quality continue QC rest the into we're sequential leaned strong the a our the of functions. adjusted the in realized our Critical processes, of and demand margin to industry improvements to acquisition from execution to to turning the Importantly, highest and experiencing, and chains EBITDA demands gross that want improvement service handle throughout confidence deliver production important quality and see Stirling of appreciation confident feeding commitment we'll engineering my to a the our and the I in, and year. in sustained got
of you We products side now processing XXX three QX. gained Turning least and And which the the cell to services are, first, includes business at remind media those across our biopreservation processing, customer back to and cell new products. revenue customers and in platforms. Sexton
mechanical our storage storage systems offering. freezers finally, nitrogen freezers which and and cold services And our includes and SciSafe comprised thaw freezers ULT Stirling devices. thawing and liquid evo our chain platform Second, cold services, management of chain and
cold customers customers end chain included by XX using using customers, and processing products. freezer new line X customers New now ULT cell customers, new users, product ThawSTAR freezer media, new XX QX users, XX XX BioStorage X now Sexton biopreservation Sterling X evo new cryogenic new new
our at unique more X,XXX reminder, customers, media year. two we direct products having a with benefit full and XXX biopreservation customers than the year As also end for largest from distributors very our last least XXXX, we to gained sold and productive new shipped
platforms each. and make for some revenue revenue three speak let our to Troy I'll comments Now qualitative about
For more incorporated and media new trials up have least cell customer clinical in at the clinical our we used processing and cell additional of at gene XXX be cell received in and our products media XXX XX therapies. from estimate applications, end processing will in than for XXXX. products XX gained been confirmation QX, customers We that biopreservation new
if range therapies. we X approved, remain our biopreservation that Sexton confident therapies media, our are annual cell XX in approved application, vials to used in approved three could date, used each and For clinical media customer also To million. biopreservation media XXX,XXX the is processing generate in revenue of and
CAR XX filings conclude of platforms are by submitted customer embedded or in saying year. I'll developers biopreservation approval the regulatory next of our be currently embedded most media to year development. which allogeneic products and expected are majority additional least T-cell the biopreservation with BLA applications media includes and this Our products in autologous the that other our at clinical in base for also CGT
able companies. can We to take role continue expect to to critical in for from risk preservation CGT in share engineered be home brew formulations reducing grows awareness as media the cocktails our play
for see two the first solutions. growth and of pending media CGT and We second our indications for also for and other as and new biopreservation products approvals treatments line recent approvals catalysts
doubled compared systems notable exposed residual cell nearly biotech customers, ULT to shipped Stirling XXXX. several unit and We our we to activities. are Again, year, thaw improving team freezers mitigation freezers than under an Turning some that ULT trained therapy issues remain speak production we're and and quality We gene our new of latent platform. will reducing our surge inherited. more in and recovery and last gained chain and focused detail issues and a freezer on companies. on of X,XXX The more supplier that addressing we our demand supply of quality hyper and scaled result this XXXX saw our in Rod custom products. Stirling cost XXX including demand quality
end week lead working very orders goal and lead by Importantly, for the June. a demand with of new reduce hard to strong, times of to remains we're three times two
and for executed nitrogen and call, excited our largest agreement a As LNX freezer for add chain an liquid storage we'll to BioLife potential rentals platforms, our evo XX freezers, agreement with cold update from gained about marketing and customers we opportunities say growth more our of to this this evo. new services, and We're last which chain topic QX. In to and three SciSafe related revenue to the storage cold services portfolio new XX we in of distributor the about throughout ULT their our the to That's have rest a CBS freezer and activities for year. sales includes offering. final capture X services, storage
platform to ability profitably optimistic services rapidly, and about demand. this is very storage remain growing SciSafe platform meet we our to scale Our
period press the services storage robust, we opportunities This agreement is and customers a issued biorepository. continue co-marketing a and U.S. about new our once platform, forward sharing optionality QX Our evo look to now is potential new with class storage services last network morning, companies parties release believe to to includes will reporting the bioprocessing we full analytics offering biotech we management benefit cross-market cold on now and and and were services. With swing. access and locations partner up our assess Biocare. program respective companies, full complementary of initiative chain list cell evo courier our the for gene Patheon, in both Research revenue World researchers in expanded have therapy wherein later our new a Marken for We executed will and specialty Institute we agreement Medical services XX% over this through cell this same Coriell the that Courier, year Quick combination shipments of year. International, defining and
and in umbilical several including apheresis group materials. collection, shippers have are other transport CGT is biologic marquee list really We platform. and growth used of plasma and The the expect continued therapies, being components, evo underway companies. end to other T-cell leading evaluations evo the of now and blood validations cord CAR of users blood a
few to validate container than most partner and will selection. leading more before, As the move next our a believe logistics shipping will platform years and evo that emerge mentioned I over we CGT companies and one approve as
for call the on present some to Troy provide activities. over other financials turn QX, to current to our comments like I Before I'd
Summit, and I at team star areas offering. and a Francisco, is better week, session wrote freezer fully One rate We from operations. control on leads to workflows is review the mid customers. of marketing to of long-term the us various our to come are we're of couple to Last customer high-capacity risk address rate new needs San for Innovation further emanate conference together distribution working Innovation line software say value can high-capacity we experts, will augment at current First, CGT our and high-capacity that for this freezer was nine Summit. products nitrogen the This developing. speak and freezers. appropriate, to and presented our we and near-term much flagship projects development strategy ISCT exhibited XX the innovate conference product unmet storage rate add and acquisitions, optimize total liquid expect have more our be manufacturing the reduce our show. further and in products inaugural result world-class can a specific where to about We'll all teams specifically identify holding in when the a in Global the to to additional hardware the where and Through of we've team to innovations our weeks, practices our and to on we'll assembled folks our smart engineering our I
We models also have payload new various product three additional of in development plan. our capacities
I'll Now pass over call Troy. the to
